Shandong province’s draft pharmaceutical industry development action plan (’15th
Five-Year’, soliciting comments) calls for accelerated development and
industrialization of monoclonal antibodies, bispecific and trispecific
antibodies, antibody-drug conjugates (ADCs), recombinant proteins, cells and genes
therapies, innovative vaccines and marine biopharmaceuticals, targeting major
infectious, respiratory, oncologic, drug‑resistant, autoimmune, metabolic and
CNS diseases. The plan flags antibody therapies for malignant tumors,
hematologic, autoimmune, metabolic, ophthalmic, neurological, cardiovascular and
anti‑infective indications as priorities and backs development of
multifunctional antibodies, antibody‑fusion proteins, nanobodies, antibodies
combinations and compound formulations, high‑concentration products and novel
ADC platforms to strengthen core technologies and industrial capacity.
